Key Points
- BioSyent director Stephen Wilton sold 805 shares at an average price of C$15.84, generating proceeds of C$12,751.20 and reducing his direct holdings by 9.27% to 7,876 shares.
- BioSyent shares opened at C$15.75, near their 52-week high of C$16.00, with a market capitalization of approximately C$178.18 million and a price-to-earnings ratio of 18.44.
- The company develops and sells healthcare products in Canada and internationally, including FeraMAX iron supplements, Tibella hormone therapy, Inofolic, RepaGyn, and Gelclair.
BioSyent Inc. (CVE:RX - Get Free Report) Director Stephen Edwin William Wilton sold 805 shares of the business's stock in a transaction on Friday, August 28th. The stock was sold at an average price of C$15.84, for a total transaction of C$12,751.20. Following the completion of the transaction, the director directly owned 7,876 shares in the company, valued at C$124,755.84. This trade represents a 9.27% decrease in their position.
BioSyent Stock Performance
RX opened at C$15.75 on Friday. The stock has a market capitalization of C$178.18 million, a price-to-earnings ratio of 18.44 and a beta of 1.00. The company has a fifty day moving average of C$14.77 and a 200 day moving average of C$14.72. BioSyent Inc. has a fifty-two week low of C$10.65 and a fifty-two week high of C$16.00. The company has a debt-to-equity ratio of 6.85, a quick ratio of 6.91 and a current ratio of 2.07.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
